What Are the Combined Health Benefits of Danshen and Sanqi?

Salvia miltiorrhiza (Danshen) and Panax notoginseng (Sanqi) are two traditional Chinese medicinal herbs frequently combined in clinical practice for their synergistic cardiovascular benefits. When administered together, these botanicals demonstrate complementary pharmacological actions that enhance microcirculation, inhibit platelet aggregation, and exert antioxidant and anti-inflammatory effects.

Danshen contains active diterpenoid quinones—primarily tanshinone IIA—and phenolic acids such as salvianolic acid B. These compounds modulate nitric oxide synthase activity, improve endothelial function, and suppress vascular smooth muscle cell proliferation. Sanqi, rich in ginsenosides (notably Rb1, Rg1, and R1) and notoginsenosides, contributes potent antiplatelet, antithrombotic, and cardioprotective properties. Its saponins stabilize atherosclerotic plaques and reduce ischemia-reperfusion injury.

Clinical evidence supports the combination’s efficacy in managing chronic stable angina pectoris and post-infarction recovery. Randomized controlled trials report improved exercise tolerance, reduced frequency of angina episodes, and enhanced left ventricular ejection fraction compared with monotherapy or conventional treatment alone. The dual herb regimen also demonstrates favorable safety profiles, though caution is warranted in patients receiving anticoagulants or antiplatelet agents due to potential additive bleeding risk.

Modern pharmacognosy research continues to elucidate molecular targets—including PI3K/Akt, NF-κB, and Nrf2 pathways—through which this herbal pair exerts its integrated vasoprotective effects. Ongoing standardization efforts aim to ensure batch-to-batch consistency of bioactive constituents, supporting broader integration into evidence-informed integrative cardiology protocols.